Therapeutic Area Commitment

Today and tomorrow

We’re committed to reducing the suffering caused by cancer and alleviating the effects of chronic inflammatory diseases. In nearly four decades of mastering biologics, we’ve delivered a portfolio of transformative medicines that have redefined these therapeutic areas.

In oncology, our accelerating biosimilar research and development will expand our portfolio into breast cancer, lung cancer, non-Hodgkin’s lymphoma, and other cancers.1 We’ll continue research and development in these areas and others, with the goal of creating more and better treatments for patients.

The highest-quality medicines

As we strive to meet the needs of patients with chronic inflammatory diseases or cancer, we’ve made it our mission to deliver only the highest-quality medicines. That’s because there’s too much on the line when it comes to these life-altering diseases.

We’ve been doing it for decades with our novel biologic medicines, and we’ll maintain that standard with our biosimilars. Patients and caregivers can count on us for the quality that they expect and depend on.

Moving forward

We’re committed to building a future with a more sustainable health care system. All patients should have cost-effective access to the medicines they need. That’s why we’re expanding access with our portfolio of biosimilar medicines for cancer and inflammatory diseases.

Reference: 1. Amgen. Our Pipeline. Accessed April 25, 2018.


Previous: impacts of biosimilars